{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-070335","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2024-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.919753+00:00","generated_at":"2026-05-31T08:53:18.039529+00:00","sec_items":["1.01","2.01","5.06","9.01","5.02","3.02","3.03","4.01","5.01","5.03"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Citius Oncology completes de-SPAC business combination; CTOR begins trading","bullets":["Citius Pharma received 65.6M shares (~92.6% ownership); 4.3M SPAC shares redeemed for ~$49.3M ($11.47 each).","Company Common Stock began trading on Nasdaq Capital Market as 'CTOR' on August 13, 2024.","Leonard Mazur appointed CEO & Chair; Jaime Bartushak CFO; Myron Holubiak Secretary/Treasurer; Myron Czuczman CMO.","Citius Pharma contributed $10M capital; waivers include LYMPHIR trademark transfer within 60 days post-closing.","71.3M shares outstanding post-closing; board of 8 directors with staggered terms; controlled company under Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-070335","json":"https://secwatch.observer/filing/0001213900-24-070335.json","markdown":"https://secwatch.observer/filing/0001213900-24-070335.md","text":"https://secwatch.observer/filing/0001213900-24-070335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/ea0211423-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:53:18.039529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8769a377c8","claim":"Cathy Jiang resigned as Director at CITIUS ONCOLOGY, INC..","evidence_excerpt":"each of Cathy Jiang and Brian Hartzband resigned as directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d920f66c8c","claim":"Brian Hartzband resigned as Director at CITIUS ONCOLOGY, INC..","evidence_excerpt":"each of Cathy Jiang and Brian Hartzband resigned as directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"db7e794ba9","claim":"Xiaofeng Yuan resigned as Chief Executive Officer at CITIUS ONCOLOGY, INC..","evidence_excerpt":"Xiaofeng Yuan resigned as Chief Executive Officer and Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"eda41c600d","claim":"Taylor Zhang resigned as Chief Financial Officer at CITIUS ONCOLOGY, INC..","evidence_excerpt":"Taylor Zhang resigned as Chief Financial Officer and a director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024070335/0001213900-24-070335-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}